Background: We investigated whether the use of respiratory fluoroquinolones was
associated with better clinical outcomes compared with the use of macrolides and β-lactams …

OBJECTIVE: To determine the role of newer fluoroquinolones (FQs) for adults with
community-acquired pneumonia (CAP) whose level of illness allows treatment with an oral …

Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the
management of community‐acquired pneumonia (CAP). Methods: Data were collected from …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

A literature search was conducted to evaluate the pharmacokinetic and pharmacodynamic
profile of the respiratory fluoroquinolones (gemifloxacin, levofloxacin and moxifloxacin) and …

Background. Fluoroquinolones have equivalent oral and intravenous bioavailability, but
hospitalized patients with community-acquired pneumonia (CAP) generally are treated …

Objective The best treatment option for hospitalized patients with community-acquired
pneumonia (CAP) has not been defined. The effectiveness of β-lactam/fluoroquinolone …

Pharmacokinetic and pharmacodynamic features are important predictors of the therapeutic
efficacy of an antibiotic. In respiratory tract infection, study of the clinical implication of …

Based on recent guidelines for the management of community-acquired pneumonia, this
study was designed to evaluate the effectiveness of a new fluoroquinolone compared with …

The new respiratory fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin,
and on the horizon, garenoxacin) offer many improved qualities over older agents such as …